Introduction
============

Osteoarthritis (OA) is a common form of degenerative joint disease affecting an estimated 151.4 million people worldwide.[@b1-oarrr-5-069] Joint pain and stiffness, together with associated loss of function and reduced quality of life, constitute the main disease burden of OA. A worldwide public health concern, OA is one of the leading causes of long-term disability that predominantly affects people of working age and older, and is thus expected to increase in prevalence as the world's population ages.[@b2-oarrr-5-069],[@b3-oarrr-5-069] Management of OA pain is therefore an important health care goal.

There are a variety of therapies available for treating pain associated with OA. Paracetamol (or acetaminophen in the US) is recommended as the initial pharmacologic therapy for mild symptoms, followed by a traditional nonsteroidal anti-inflammatory drug (tNSAID) or cyclooxygenase-2-selective NSAID.[@b2-oarrr-5-069],[@b4-oarrr-5-069] The response to NSAIDs, as well as associated side effects, can vary substantially among individuals, and there is evidence that patients can be classified as responders or nonresponders to particular agents.[@b5-oarrr-5-069] The fact that therapies vary in their benefit--risk profiles, and individual patients in their responses to these therapies, reinforces the need for careful selection of therapy for each patient.

The focus of clinical trial research of OA therapies, such as NSAIDs, has typically centered on the response to treatment (relief of pain), while the consequences of inadequate pain relief are less well investigated. Moreover, the outcomes of clinical trials do not always directly translate to the real world, where patients may use their pain medication intermittently and have comorbidities that influence tolerability.

The objectives of this study were to concurrently evaluate the perceptions of physicians and patients regarding response to OA therapy in a real-world clinical care setting, as measured by satisfaction with the current control of OA among patients receiving tNSAIDs. Exploration of patient and physician satisfaction with tNSAIDs may offer information relevant for individualized management of OA.

Methods
=======

This analysis drew on data from the 2009 Adelphi Real World Arthritis Disease Specific Program (DSP). The DSPs, described in detail elsewhere,[@b6-oarrr-5-069] are multinational cross-sectional surveys of physicians and patients, conducted every 1--2 years to understand current clinical practice for common chronic diseases. The physicians who participated in the 2009 arthritis DSP were recruited by telephone from public lists of health care professionals, and included primary care physicians, rheumatologists, and orthopedists. To be eligible, physicians had to have been qualified as a physician from 1971--2007, to see a minimum of ten patients with OA per month, and to be personally involved in the drug management for arthritis. Participating physicians were asked to identify, and complete a written survey for, consecutive patients with rheumatoid arthritis or OA at any site; these patients, in turn, were asked to participate by completing a written patient survey. Physicians did not see or influence patient responses, and patient survey completion was voluntary.

The DSP was conducted under the European Pharmaceutical Market Research Association (EphMRA) code of conduct, thus ensuring compliance with Health Insurance Portability and Accountability Act (HIPAA) and all European data protection requirements. Patients were asked to provide consent before participating. Physicians were compensated for their participation in the study according to accepted research rates.

Patients with OA in Germany, Spain, and the UK who reported using a tNSAID were included in the study. Patients using disease-modifying agents and biologics were excluded. The diagnosis and severity of OA were established by the treating physicians; specification of the diagnostic test(s) leading to the OA diagnosis and severity assessment were not required.

Patients and their physicians completed standardized questionnaires to collect data on OA management, including clinical characteristics, prescribing behaviors, treatment patterns, patient-reported outcomes, and health-related quality of life. For each patient, physicians were asked, "Which of the following best describes your satisfaction with the current control of this patient's arthritis?" Each patient was asked, "Overall, are you satisfied with the current control of your arthritis medicine?" The level of satisfaction with OA control was reported by both physicians and patients as (1) satisfied; (2) not satisfied, but I believe this is the best that can be achieved; or (3) not satisfied, and I believe better control can be achieved. The meaning of the word "control" was not specified in the questionnaire and therefore was based on the physicians' and patients' subjective perception. The satisfaction question permitted each physician and patient to interpret the word "control" according to their priorities. Other patient-reported outcomes included a generic health-related quality of life instrument, the EuroQol EQ-5D;[@b7-oarrr-5-069] the Health Assessment Questionnaire (HAQ);[@b8-oarrr-5-069] and the Western Ontario and McMaster Universities OA Index (Likert scale).[@b9-oarrr-5-069]

Study questionnaires were developed in English and then translated into the language of the study country by a local DSP fieldwork agency. A second independent translation agency linguistically validated each translated document. All responses were deidentified and anonymized to preserve patient confidentiality and to avoid bias at the data collection and analysis phases.

Statistical analyses
--------------------

Descriptive statistics were used to describe the sample of patients using tNSAIDs. Categorical and continuous variables were compared using the Chi-squared test and *t*-test, respectively. Cohen's κ coefficient with 95% confidence interval was derived to determine agreement between patient and physician in satisfaction with current control of OA. Analyses were carried out using Stata version 10.1 (Stata Corp LP, College Station, TX, USA) and SAS software version 9.2 (SAS Institute Inc, Cary, NC, USA).

Results
=======

A total of 361 physicians participated in the study, including primary care physicians (34%), rheumatologists (54%), and orthopedists (12%). They completed study questionnaires for 1572 patients, of whom 1119 (71.2%) completed the corresponding patient questionnaire. Among the patients completing the patient questionnaire, 713 (63.7%) were treated with a tNSAID and were included in the analyses described here. Results by country are reported in [Tables S1](#SD1-oarrr-5-069){ref-type="supplementary-material"}[](#SD2-oarrr-5-069){ref-type="supplementary-material"}--[S3](#SD3-oarrr-5-069){ref-type="supplementary-material"}.

Patient demographic and clinical characteristics are summarized in [Table 1](#t1-oarrr-5-069){ref-type="table"} for the 705/713 patients with recorded OA severity, graded by physicians as mild (n = 214, 30%) versus moderate (n = 389, 55%) or severe (n = 102, 14%). Patients ranged in age from 36--94 years, with a mean (standard deviation) age of 65.5 (11.0) years; 60% were women; 86% were white; and the mean (standard deviation) body mass index was 27.7 (4.7). The time since the diagnosis of OA ranged from 0--27 years, with a median of 3.5 years. Patients with mild as compared with moderate or severe OA were younger, more likely to be employed, and less likely to be obese or to have a concomitant gastric condition or history of cardiovascular disease; moreover, they had less need for analgesia and were less disabled (by HAQ score) ([Table 1](#t1-oarrr-5-069){ref-type="table"}).

All patients were taking a tNSAID, most commonly diclofenac (46%), ibuprofen (37%), or naproxen (6%). Sixty percent of patients reported good compliance (ie, "I follow the instruction fully and give my medication every chance to work"), including 63% with mild OA and 59% with moderate to severe OA ([Table 2](#t2-oarrr-5-069){ref-type="table"}).

Results of patient-reported measures, while variable, indicated persistent arthritis-associated disability for many patients. The mean (standard deviation) score on the generic EQ-5D was 0.59 (0.28) on a scale of zero (dead) to one (perfect health), while mean (standard deviation) score for patient functioning on the HAQ was 1.32 (0.68) on a scale of zero (no disability) to three (complete disability). On the Western Ontario and McMaster Universities OA Index (score of zero representing best response), the average score for pain was 5.7 on a zero to 20 scale and 2.5 for stiffness on a zero to eight scale; the average score for physical functioning had a mean score of 16.1 on a zero to 68 scale.

Physicians recorded dissatisfaction with the current control of arthritis for one-third of patients (n = 243, 34%; [Table 3](#t3-oarrr-5-069){ref-type="table"}). Inadequate response was the most common reason cited for dissatisfaction, while for most of these patients, the prescribing physician believed that the current state of control was the best that could be achieved ([Table 3](#t3-oarrr-5-069){ref-type="table"}). The replies of patients regarding satisfaction with their arthritis medication were proportionately similar to those of physicians (37% dissatisfied). Patient and physician assessments were the same in 70% of cases; the κ coefficient was 0.34 (95% confidence interval 0.26--0.41), indicating fair agreement. Overall, for 351/688 (51%) of patients, either the physician or the patient, or both, were dissatisfied. Only one-third of dissatisfied patients believed that better control of their arthritis could be achieved ([Table 3](#t3-oarrr-5-069){ref-type="table"}).

Dissatisfaction with OA control was significantly more frequent for patients with moderate or severe OA than for those with mild OA ([Table 3](#t3-oarrr-5-069){ref-type="table"}). Physicians recorded dissatisfaction with arthritis control for 14% of patients with mild and 43% of those with moderate to severe OA; the causes of dissatisfaction were similar among physicians regardless of OA severity. Among patients themselves, dissatisfaction was expressed by 24% of those with mild and 43% of those with moderate or severe OA. Patient and physician assessments were more often the same for patients with mild OA (76% versus 66% of those with moderate or severe disease). For 31% of patients with mild and 60% of those with moderate or severe OA, either the physician or the patient, or both, were dissatisfied.

Discussion
==========

This study provides comprehensive data from both physicians and consulting patients in three European countries on physician prescribing behaviors and satisfaction with control of OA provided by tNSAID treatment. It was found that for one-half of patients, either the physician, patient, or both were dissatisfied with OA control provided by tNSAIDs. Not surprisingly, this figure was higher for those patients with moderate or severe OA (60%) than for those with mild disease (31%). Thus, despite multiple options for tNSAID therapy, there is still an unmet medical need for alternative treatment options for patients and physicians to adequately treat OA.

The majority of physicians and patients who reported dissatisfaction in this survey also reported that they believed that the current level of OA control was the best that could be achieved for the patient. Interestingly, fewer physicians (21%) than patients (36%) believed that better control could be achieved. Given the importance of the patient--physician relationship, further research should explore the apparent disconnect suggested by the κ coefficient of 0.34, indicating only fair agreement between patient and physician assessments regarding satisfaction with current control of OA.

Satisfaction with control of OA was measured as a proxy for physicians' and patients' assessments about the effectiveness of therapy; conversely, dissatisfaction with control of OA served as a proxy for inadequate response. In a prior study, Dworkin et al used a patient-completed global assessment of treatment satisfaction to assess response to therapy with a lidocaine patch for knee OA and chronic low back pain.[@b10-oarrr-5-069] They found that improvements in measures of pain intensity, pain relief, and interference with physical functioning each made independent contributions to treatment satisfaction, whereas adverse events and improvements in emotional functioning and sleep did not. Results of other studies indicate that measures of treatment satisfaction improve concurrently with improvements in pain, function, and quality of life.[@b11-oarrr-5-069],[@b12-oarrr-5-069]

Possible reasons for dissatisfaction were evaluated and it was found that inadequate response to treatment was the most common reason reported by physicians. Dissatisfaction with treatment can, in turn, lead to noncompliance, increased health care resource use such as repeat clinical visits, and switching to other therapies for pain. Indeed, switching is common for patients receiving tNSAIDs.[@b13-oarrr-5-069],[@b14-oarrr-5-069]

The strengths of this study are the inclusion of large numbers of physicians and their patients as part of a well-established survey, the inclusion of different types of health care providers, a real-world population that included some patients who might not be eligible for randomized clinical trials of treatment efficacy, and the concurrent assessment of physicians and patients for their satisfaction with control of arthritis. Similar to findings in other studies, it was found that patient and physician assessments may differ; this is true for global assessments in rheumatoid arthritis.[@b15-oarrr-5-069]

Limitations of this purely descriptive study include the potential for recall bias, misunderstanding of survey questions, and other common limitations associated with use of survey instruments, including the potential for selection bias leading to lack of generalizability because only those patients who agreed to complete the questionnaires were included. The results may not represent all regions or practices in the selected countries. Some data were missing, including OA severity for eight patients and some patient self-assessment data, including HAQ data for 30/713 (4%) patients; 21/713 (3%) patients did not reply to the satisfaction question, with matched physician--patient responses to the satisfaction question missing for 25/713 (4%) of patients. Moreover, it was not assessed which joints were affected by OA nor the effect of nonpharmacologic modalities of pain relief used in conjunction with tNSAIDs. Finally, patients with moderate and severe OA were grouped together because of the small numbers with severe OA.

Conclusion
==========

This study found there was dissatisfaction with the control of arthritis for 51% of patients receiving current tNSAID therapy, including 60% of those with moderate or severe OA, as expressed by physicians or patients or both. Dissatisfaction was largely related to treatment effectiveness (inadequate response); issues of tolerability were less commonly linked to dissatisfaction by physicians. Further research is needed to explore inadequate control of OA by tNSAIDs. In particular, the associations between inadequate control and outcomes such as uncontrolled pain, repeat physician visits, health care resource use, noncompliance, and switching to other therapies warrant further investigation.

Supplementary tables
====================

###### 

Characteristics of the study patient population, overall and by country[a](#tfn16-oarrr-5-069){ref-type="table-fn"}

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Characteristic[a](#tfn16-oarrr-5-069){ref-type="table-fn"}               Total\      Germany\      Spain\      UK\           *P*                                     
                                                                           (n = 713)   (n = 344)     (n = 252)   (n = 117)                                             
  ------------------------------------------------------------------------ ----------- ------------- ----------- ------------- ----- ------------- ----- ------------- ---------
  Age, mean (SD) years                                                     713         65.5 (11.0)   344         64.8 (11.1)   252   66.5 (11.1)   117   65.1 (10.4)   NS

   36--55 years                                                                        146 (20.5)                71 (20.6)           51 (20.2)           24 (20.5)     

   56--75 years                                                                        428 (60.0)                212 (61.6)          147 (58.3)          69 (59.0)     

   76--85 years                                                                        123 (17.3)                54 (15.7)           46 (18.3)           23 (19.7)     

   \>85 years                                                                          16 (2.2)                  7 (2.0)             8 (3.2)             1 (0.9)       

  Sex, female                                                              712         427 (59.9)    344         200 (58.1)    251   169 (67.3)    117   58 (49.6)     0.01

  Race, white                                                              713         611 (85.7)    344         337 (98.0)    252   177 (70.2)    117   97 (82.9)     \<0.001

   Spanish/Hispanic                                                                    66 (9.3)                  1 (0.3)             64 (25.4)           1 (0.9)       

   Other                                                                               36 (5.0)                  6 (1.7)             11 (4.4)            19 (16.2)     

  Employed                                                                 707         170 (23.8)    340         91 (26.8)     251   48 (19.1)     116   31 (26.7)     NS

  Smoker                                                                   692         164 (23.0)    336         84 (25.0)     242   61 (26.4)     114   19 (16.7)     NS

  BMI, mean (SD)                                                           701         27.7 (4.7)    343         28.3 (5.2)    249   27.3 (3.6)    109   26.4 (4.7)    \<0.001

   Obese (BMI ≥ 30)                                                                    170 (24.3)                99 (28.9)           52 (20.9)           19 (17.4)     

  Concomitant condition                                                                                                                                                

   GI condition                                                            713         171 (24.0)    344         67 (19.5)     252   78 (31.0)     117   26 (22.2)     0.005

   History of CV disease                                                   713         404 (56.7)    344         203 (59.0)    252   156 (61.9)    117   45 (38.5)     \<0.001

    Hypertension                                                           404         333 (82.4)    203         173 (85.2)    156   121 (77.6)    45    39 (86.7)     NS

   Depression/anxiety                                                      284         78 (27.5)     122         25 (20.5)     124   43 (34.7)     38    10 (26.3)     0.04

  Other medication                                                         713                       344                       252                 117                 

   Gastroprotective agent                                                              335 (47.0)                111 (32.3)          184 (73.0)          40 (34.2)     \<0.001

   Cardiovascular agent                                                                375 (52.6)                182 (52.9)          138 (54.8)          55 (47.0)     NS

   Lipid-lowering agent                                                                95 (13.3)                 50 (14.5)           39 (15.5)           6 (5.1)       0.02

  OA severity,[b](#tfn17-oarrr-5-069){ref-type="table-fn"} mild            705         214 (30.0)    342         99 (28.9)     247   77 (31.2)     116   38 (32.8)     \<0.001

   Moderate                                                                            389 (54.6)                170 (49.7)          148 (59.9)          71 (61.2)     

   Severe                                                                              102 (14.3)                73 (21.3)           22 (8.9)            7 (6.0)       

  Current need for analgesia[b](#tfn17-oarrr-5-069){ref-type="table-fn"}                                                                                               

   Mean (SD)                                                               665         4.2 (2.1)     339         3.8 (2.1)     210   4.6 (2.1)     116   4.6 (2.0)     \<0.001

   0--2.9 (none)                                                           665         174 (24.4)    339         112 (33.0)    210   39 (18.6)     116   23 (19.8)     \<0.001

   3--3.9                                                                              110 (15.4)                62 (18.3)           30 (14.3)           18 (15.5)     

   4--5.9                                                                              190 (26.7)                93 (27.4)           61 (29.0)           36 (31.0)     

   6--7.9                                                                              163 (22.9)                61 (18.0)           71 (33.8)           31 (26.7)     

   8--10 (strongest need)                                                              28 (3.9)                  11 (3.2)            9 (4.3)             8 (6.9)       

  Osteoarthritis, knee                                                     713         472 (66.2)    344         226 (65.7)    252   175 (69.4)    117   71 (60.9)     NS

  EQ-5D, mean (SD)[c](#tfn18-oarrr-5-069){ref-type="table-fn"}             713         0.59 (0.28)   344         0.61 (0.27)   252   0.55 (0.30)   117   0.61 (0.28)   \<0.001

  HAQ, mean (SD)[c](#tfn18-oarrr-5-069){ref-type="table-fn"}               713         1.32 (0.68)   344         1.26 (0.68)   252   1.37 (0.63)   117   1.37 (0.77)   \<0.001

   0.0--0.9                                                                713         245 (35.9)    344         132 (39.4)    252   69 (29.1)     117   44 (39.6)     0.02

   1.0--1.9                                                                            322 (47.1)                148 (44.2)          132 (55.7)          42 (37.8)     

   2.0--2.9                                                                            114 (16.7)                53 (15.8)           36 (15.2)           25 (22.5)     

   3.0                                                                                 2 (0.3)                   2 (0.6)             0 (0.0)             0 (0.0)       

  WOMAC, mean (SD)[c](#tfn18-oarrr-5-069){ref-type="table-fn"}             519         29.1 (17.2)   241         29.6 (16.5)   190   27.7 (16.5)   88    30.3 (19.5)   NS

   Pain                                                                    552         5.7 (3.7)     263         5.6 (3.4)     196   5.7 (3.6)     93    5.9 (20.0)    NS

   Stiffness                                                               531         2.5 (1.7)     248         2.4 (1.7)     192   2.6 (1.6)     91    2.8 (1.7)     NS

   Physical function                                                       681         16.1 (4.2)    322         16.4 (14.4)   245   15.5 (13.7)   114   16.6 (15.0)   NS
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

**Notes:** *P*-value calculated using the Chi-squared test for categorical values and *t*-test for continuous variables;

values are number (%) of patients unless otherwise indicated;

physician assessment;

patient self-assessment.

**Abbreviations:** BMI, body mass index; CV, cardiovascular condition; EQ-5D, EuroQol health-related quality of life (score range: zero \[dead\] to one \[perfect health\]); GI, gastrointestinal; HAQ, Health Assessment Questionnaire (scale: zero \[no disability\] to three \[complete disability\]); OA, osteoarthritis; WOMAC, Western Ontario and McMaster Universities OA Index (score range \[zero is best\]: pain zero to 20; stiffness zero to eight; physical function zero to 68); NS, not statistically significant.

###### 

Traditional nonsteroidal anti-inflammatory drug use, overall and by country[a](#tfn20-oarrr-5-069){ref-type="table-fn"}

  --------------------------------------------------------------------------
  Medications    Total\       Germany\     Spain\      UK\         *P*
                 (n = 713)    (n = 344)    (n = 252)   (n = 117)   
  -------------- ------------ ------------ ----------- ----------- ---------
  Diclofenac     325 (45.6)   203 (59.0)   64 (25.4)   58 (49.6)   \<0.001

  Ibuprofen      262 (36.8)   133 (38.7)   97 (38.5)   32 (27.4)   NS

  Naproxen       41 (5.8)     2 (0.6)      23 (9.1)    16 (13.7)   \<0.001

  Meloxicam      33 (4.6)     4 (1.2)      23 (9.1)    6 (5.1)     \<0.001

  Aceclofenac    26 (3.7)     2 (0.6)      24 (9.5)    0 (0.0)     \<0.001

  Ketoprofen     16 (2.2)     2 (0.6)      14 (5.6)    0 (0.0)     \<0.001

  Indomethacin   12 (1.7)     7 (2.0)      5 (2.0)     0 (0.0)     NS

  Piroxicam      12 (1.7)     1 (0.3)      7 (2.8)     4 (3.4)     0.02

  Etodolac       3 (0.4)      0 (0.0)      0 (0.0)     3 (2.6)     \<0.001
  --------------------------------------------------------------------------

**Note:**

Patients could be on more than one drug.

**Abbreviation:** NS, not statistically significant.

###### 

Physician and patient satisfaction with treatments prescribed, overall and by country[a](#tfn22-oarrr-5-069){ref-type="table-fn"}

  ------------------------------------------------------------------------------------------------------------------------------
                                                                    Total\       Germany\     Spain\       UK\         *P*
                                                                    (n = 713)    (n = 344)    (n = 252)    (n = 117)   
  ----------------------------------------------------------------- ------------ ------------ ------------ ----------- ---------
  **Physicians' responses**                                         (n = 709)    (n = 342)    (n = 251)    (n = 116)   

  Satisfied                                                         466 (65.7)   234 (68.4)   153 (60.7)   79 (67.5)   NS

  Dissatisfied                                                      243 (34.3)   108 (31.6)   98 (39.0)    37 (31.9)   

   Believe this is the best that can be achieved for this patient   191 (78.6)   77 (71.3)    82 (83.7)    32 (86.5)   

   Believe better control can be achieved for this patient          52 (21.4)    31 (28.7)    16 (16.3)    5 (13.5)    

  Causes of dissatisfaction                                         (n = 243)    (n = 108)    (n = 98)     (n = 37)    

   Inadequate response                                              135 (55.6)   50 (46.3)    63 (64.3)    22 (59.5)   0.03

   Side effects                                                     27 (11.1)    10 (9.3)     9 (9.2)      8 (21.6)    NS

   Poor tolerance                                                   19 (7.8)     5 (4.6)      11 (11.2)    3 (8.1)     NS

   Other                                                            58 (23.5)    39 (36.1)    15 (15.3)    4 (8.1)     \<0.001

   Not stated                                                       22 (9.1)     7 (6.5)      10 (10.2)    5 (13.5)    NS

  **Patients' responses**                                           (n = 692)    (n = 338)    (n = 242)    (n = 112)   

  Satisfied                                                         433 (62.6)   225 (66.6)   137 (56.6)   71 (63.4)   0.05

  Dissatisfied                                                      259 (37.4)   113 (33.4)   105 (43.4)   41 (36.6)   

   Believe this is best that can be achieved for my arthritis       157 (64.1)   72 (63.7)    60 (57.1)    25 (61.0)   NS

   Believe better control can be achieved for my arthritis          88 (35.9)    37 (32.7)    35 (33.3)    16 (39.0)   

  **Physicians' and patients' responses**                           (n = 688)    (n = 336)    (n = 241)    (n = 111)   

  Concordant                                                        478 (69.1)   242 (71.6)   156 (64.5)   80 (71.4)   

   Both satisfied                                                   337 (70.5)   180 (74.4)   98 (62.8)    59 (73.8)   

   Both dissatisfied                                                141 (29.5)   62 (25.6)    58 (37.2)    21 (26.3)   

  Discordant                                                        210 (30.3)   94 (27.8)    85 (35.1)    31 (27.7)   

   Physician satisfied, patient dissatisfied                        117 (55.7)   50 (53.2)    47 (55.3)    20 (64.5)   

   Physician dissatisfied, patient satisfied                        93 (44.3)    44 (46.8)    38 (44.7)    11 (35.5)   
  ------------------------------------------------------------------------------------------------------------------------------

**Note:**

Values are n (%).

**Abbreviation:** NS, not statistically significant.

These analyses were funded by Merck Sharp and Dohme Corp, (Whitehouse Station, NJ, USA); the DSP survey was funded by Merck Sharp and Dohme Corp, together with other pharmaceutical companies.

**Disclosure**

SD Taylor, SV Everett, and DJ Watson are employees of Merck Sharp and Dohme Corp, a subsidiary of Merck and Co, Inc (Whitehouse Station, NJ, USA); TN Taylor has no conflicts of interest to declare; G Taylor-Stokes is an employee of Adelphi Real World. Medical writing and editorial assistance was provided by Elizabeth V Hillyer, which was funded by Merck Sharp and Dohme Corp.

###### 

Characteristics of the study patient population, overall and by severity of osteoarthritis[a](#tfn2-oarrr-5-069){ref-type="table-fn"}

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Characteristic[a](#tfn2-oarrr-5-069){ref-type="table-fn"}               Total\      Mild OA[b](#tfn3-oarrr-5-069){ref-type="table-fn"}\   Moderate/severe OA[b](#tfn3-oarrr-5-069){ref-type="table-fn"}\   *P*                               
                                                                          (n = 705)   (n = 214)                                             (n = 491)                                                                                          
  ----------------------------------------------------------------------- ----------- ----------------------------------------------------- ---------------------------------------------------------------- ------------- ----- ------------- ---------
  Age, mean (SD)                                                          705         65.5 (11.0)                                           214                                                              62.1 (11.0)   491   66.9 (10.8)   \<0.001

   36--55 years                                                                       146 (20.7)                                                                                                             65 (30.4)           81 (16.5)     \<0.001

   56--75 years                                                                       421 (59.7)                                                                                                             123 (57.5)          298 (60.7)    

   76--85 years                                                                       122 (17.3)                                                                                                             22 (10.3)           100 (20.4)    

   \>85 years                                                                         16 (2.3)                                                                                                               4 (1.9)             12 (2.4)      

  Sex, female                                                             705         420 (59.6)                                            214                                                              129 (60.3)    491   291 (59.3)    NS

  Race, white                                                             705         605 (85.8)                                            214                                                              177 (82.7)    491   428 (87.2)    NS

   Spanish/Hispanic                                                                   64 (9.1)                                                                                                               21 (9.8)            43 (8.8)      

   Other                                                                              34 (4.8)                                                                                                               15 (7.0)            19 (3.9)      

  Employed                                                                705         170 (24.1)                                            214                                                              65 (30.4)     491   105 (21.4)    0.012

  Smoker                                                                  705         164 (23.3)                                            214                                                              56 (26.2)     491   108 (22.0)    NS

  BMI, mean (SD)                                                          705         27.7 (4.7)                                            214                                                              26.8 (4.0)    491   28.1 (4.9)    \<0.001

  Obese (BMI ≥ 30 kg/m^2^)                                                705         169 (24.0)                                            214                                                              38 (17.8)     491   131 (26.7)    0.024

  Concomitant condition                                                                                                                                                                                                                        

   GI condition                                                           705         170 (24.1)                                            214                                                              32 (15.0)     491   138 (28.1)    \<0.001

   History of CV disease                                                  705         403 (57.2)                                            214                                                              100 (46.7)    491   303 (61.7)    \<0.001

    Hypertension                                                          411         332 (80.8)                                            102                                                              78 (76.5)     309   254 (82.2)    NS

   Depression/anxiety                                                     277         75 (27.1)                                             64                                                               19 (29.7)     213   56 (26.3)     NS

  Other medication                                                        705                                                               214                                                                            491                 

   Gastroprotective agent                                                             330 (46.8)                                                                                                             75 (35.1)           255 (51.9)    \<0.001

   Cardiovascular agent                                                               371 (52.6)                                                                                                             92 (43.0)           279 (56.8)    \<0.001

   Lipid-lowering agent                                                               94 (13.3)                                                                                                              14 (6.5)            80 (16.3)     \<0.001

  Current need for analgesia[b](#tfn3-oarrr-5-069){ref-type="table-fn"}                                                                                                                                                                        

   0--2.9 (none)                                                          705         172 (24.4)                                            214                                                              93 (43.5)     491   79 (16.1)     \<0.001

   3--3.9                                                                             107 (15.2)                                                                                                             44 (20.6)           63 (12.8)     

   4--5.9                                                                             190 (27.0)                                                                                                             42 (19.6)           148 (30.1)    

   6--7.9                                                                             160 (22.7)                                                                                                             20 (9.4)            140 (28.5)    

   8--10 (strongest need)                                                             28 (4.0)                                                                                                               0 (0.0)             28 (5.7)      

  Osteoarthritis, knee                                                    705         467 (66.2)                                            214                                                              124 (57.9)    491   343 (69.9)    0.002

  Osteoarthritis, hip                                                     705         310 (44.0)                                            214                                                              64 (29.9)     491   246 (50.1)    n/a

  HAQ[c](#tfn4-oarrr-5-069){ref-type="table-fn"}                          683                                                               205                                                                            470                 

   0.0--0.9                                                                           245 (36.0)                                                                                                             124 (60.5)          119 (25.3)    \<0.001

   1.0--1.9                                                                           322 (47.1)                                                                                                             67 (32.7)           250 (53.2)    

   2.0--2.9                                                                           114 (16.7)                                                                                                             14 (6.8)            99 (21.1)     

   3.0                                                                                2 (0.29)                                                                                                               0 (0.0)             2 (0.43)      
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

**Notes:** *P*-value calculated using the Chi-squared test for categorical values and *t*-test for continuous variables;

values are number (%) of patients (eight patients were missing data on OA severity);

physician assessment;

patient self-assessment.

**Abbreviations:** BMI, body mass index; CV, cardiovascular condition; GI, gastrointestinal; HAQ, Health Assessment Questionnaire (scale: zero \[no disability\] to three \[complete disability\]); n/a, not assessed; NS, not statistically significant; SD, standard deviation; OA, osteoarthritis.

###### 

Self-reported patient compliance for prescribed osteoarthritis medications, overall and by severity of osteoarthritis[a](#tfn7-oarrr-5-069){ref-type="table-fn"}

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Characteristic                                                                                                   Total\       Mild OA[b](#tfn8-oarrr-5-069){ref-type="table-fn"}\   Moderate/severe OA[b](#tfn8-oarrr-5-069){ref-type="table-fn"}\
                                                                                                                   (n = 713)    (n = 214)                                             (n = 491)
  ---------------------------------------------------------------------------------------------------------------- ------------ ----------------------------------------------------- ----------------------------------------------------------------
  I follow the instruction fully and give my medication every chance to work                                       429 (60.2)   135 (63.1)                                            288 (58.7)

  I follow the instructions fully but sometimes forget to take the medication on the right day                     154 (21.6)   43 (20.1)                                             110 (22.4)

  I follow the instructions fully but am quick to give up if it doesn't work straight away or I get side effects   53 (7.4)     13 (6.1)                                              40 (8.2)

  It varies, I tend to take my medication for a while and then stop and/or take it when I remember                 26 (3.7)     5 (2.3)                                               20 (4.1)

  It varies, I tend to take my medication only when symptoms occur or worsen                                       54 (7.6)     21 (9.8)                                              33 (6.7)

  It varies, I tend to take my medication only when I know I may get a flare up/worsening of my arthritis          14 (2.0)     4 (1.9)                                               10 (2.0)
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

**Notes:** There were no statistically significant differences between patients with mild versus moderate/severe OA (Chi-squared test);

values are number (%) of patients (eight patients were missing data on OA severity);

physicians graded severity of OA as mild, moderate, or severe.

**Abbreviation:** OA, osteoarthritis.

###### 

Physician and patient satisfaction with treatments prescribed[a](#tfn11-oarrr-5-069){ref-type="table-fn"}

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                                                                                        Total\       Mild OA[b](#tfn12-oarrr-5-069){ref-type="table-fn"}\   Moderate/severe OA[b](#tfn12-oarrr-5-069){ref-type="table-fn"}\   *P*
                                                                                        (n = 713)    (n = 214)                                              (n = 491)                                                         
  ------------------------------------------------------------------------------------- ------------ ------------------------------------------------------ ----------------------------------------------------------------- ---------
  **Physicians' responses**                                                             (n = 709)    (n = 213)                                              (n = 488)                                                         

  Satisfied                                                                             466 (65.7)   183 (85.9)                                             278 (57.0)                                                        \<0.001

  Dissatisfied                                                                          243 (34.3)   30 (14.1)                                              210 (43.0)                                                        

   Believe this is the best that can be achieved for this patient                       191 (78.6)   22 (73.3)                                              167 (79.5)                                                        

   Believe better control can be achieved for this patient                              52 (21.4)    8 (26.7)                                               43 (20.5)                                                         

  Causes of dissatisfaction                                                             (n = 243)    (n = 30)                                               (n = 210)                                                         

   Inadequate response                                                                  135 (55.6)   16 (53.3)                                              116 (55.2)                                                        NS

   Side effects                                                                         27 (11.1)    3 (10.0)                                               24 (11.4)                                                         NS

   Poor tolerance                                                                       19 (7.8)     2 (6.7)                                                16 (7.6)                                                          NS

   Other                                                                                58 (23.5)    8 (26.7)                                               49 (23.3)                                                         NS

   Not stated                                                                           22 (9.1)     1 (3.3)                                                21 (10)                                                           NS

  **Patients' responses**                                                               (n = 692)    (n = 208)                                              (n = 478)                                                         

  Satisfied                                                                             433 (62.6)   158 (76.0)                                             273 (57.1)                                                        \<0.001

  Dissatisfied                                                                          259 (37.4)   50 (24.0)                                              205 (42.9)                                                        

   Believe this is best that can be achieved for my arthritis                           157 (64.1)   31 (66.0)                                              125 (64.1)                                                        \<0.001

   Believe better control can be achieved for my arthritis                              88 (35.9)    16 (34.0)                                              70 (35.9)                                                         

  **Physicians' and patients' responses[c](#tfn13-oarrr-5-069){ref-type="table-fn"}**   (n = 688)    (n = 207)                                              (n = 475)                                                         

  In agreement                                                                          478 (69.1)   158 (76.3)                                             315 (66.3)                                                        \<0.001

   Both satisfied                                                                       337 (70.5)   143 (69.1)                                             192 (40.4)                                                        

   Both dissatisfied                                                                    141 (29.5)   15 (7.3)                                               123 (25.9)                                                        

  Not in agreement                                                                      210 (30.3)   49 (23.7)                                              160 (33.7)                                                        

   Physician satisfied, patient dissatisfied                                            117 (55.7)   34 (16.4)                                              82 (17.3)                                                         

   Physician dissatisfied, patient satisfied                                            93 (44.3)    15 (7.3)                                               78 (16.4)                                                         
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

**Notes:** *P*-value comparing mild versus moderate/severe (Chi-squared test);

values are number (%) of patients (eight patients were missing data on OA severity);

physicians graded severity of OA as mild, moderate, or severe (severity grade responses missing for eight patients);

Cohen's κ coefficient = 0.34 (95% confidence interval 0.26--0.41).

**Abbreviations:** OA, osteoarthritis; NS, not statistically significant.
